Tumor‐infiltrating eTregs highly expressed PD‐1 and that the proliferation and immunosuppressive activity of PD‐1+ eTregs could be reinforced by anti‐PD‐1 mAb therapy in patients with GC. This evidence concerns the gene PDCD1 and gastric cancer.